FDA Compliant Handling of Out-of-Trend Results in Pharmaceutical Quality Control
This webinar will discuss the FDA requirements and guidelines for investigating Out-of-trend (OOT) results in the pharmaceutical laboratory. It will also cover FDA-compliant documentation of OOT, failure investigations, root causes, and CAPA.
- FDA regulations and guidelines.
- FDA's final Guidance for Industry: Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production.
- Difference between OOS and OOT results.
- Developing SOPs for OOT situations and laboratory failures.
- Investigating OOT results: what and how.
- Retesting of OOT results.
- Using historical data for OOT evaluation.
- Using QC samples and product control charts for evaluation.
- Developing corrective and preventive action plans.
- Finding the root cause for OOT results.
- Strategies to avoid OOS situations BEFORE they occur.
- FDA-compliant documentation of OOS, OOT, failure investigations, root causes, and CAPA.
FDA's guidance on OOS test results requires failure investigations and other steps for Out-of-Specification (OOS) and Out-of-trend (OOT) results. While most companies are familiar with and have procedures for OOS results, this is not the case for OOT situations. The guide states: "Although the subject of this document is OOS results, much of the guidance may be useful for examining results that are out of trend". Managing OOT results also helps to avoid time-consuming OOS results. The industry is unsure how to interpret and implement the FDA guidance.
This session will equip you with the knowledge and comprehensive understanding of FDA requirements for Out-of-Trend Results in pharmaceutical quality control.
- Lab Supervisors and Managers
- QA managers and personnel
- Pharmaceutical R&D personnel
- Documentation
- Consultants
- Contract laboratories
- CROs
Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation.
Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries.
Upcoming Webinars
By Melveen Stevenson
Date: March 26, 2025
By Charles H. Paul
Date: March 26, 2025
By Marcia Zidle
Unlock Employee Loyalty: Stay Interviews Will Keep Them Engaged Before They Start Looking Elsewhere!
Date: March 26, 2025
By Don Phin
Date: March 27, 2025
By Dr. Susan Strauss
Date: March 28, 2025
By Beverly Beuermann-King
Date: March 28, 2025
By Dev Strischek
Date: March 31, 2025
By Cathy Horwitz
Date: March 31, 2025
By Ginette M. Collazo
Date: April 2, 2025
By Jonnie Keith
Date: April 2, 2025
By Edlyn McGarity
Date: April 2, 2025
By Marcia Zidle
Date: April 3, 2025
By Justin Muscolino
Date: April 7, 2025
By Diane L. Dee
Date: April 7, 2025
By Carolyn Troiano
Date: April 8, 2025
By Dr. Susan Strauss
Date: April 8, 2025
By Margie Faulk
Date: April 9, 2025
By Edwin Waldbusser
Date: April 10, 2025
By Terry Winship
Date: April 11, 2025
By Erica Chisolm & Vanessa Hardiman
Date: April 11, 2025
By Wendy Sellers
Date: April 14, 2025
By Dr. Susan Strauss
Date: April 14, 2025
By Mark Gorkin
Date: April 14, 2025
By Melveen Stevenson
Date: April 15, 2025
By Marcia Zidle
Date: April 17, 2025
By Carolyn Troiano
Date: April 21, 2025
By Don Phin
Date: April 21, 2025
By Cathy Horwitz
Date: April 22, 2025
